Also, an intronic SNP (rs2863344) in PDE4DIP has been associated with response to capecitabine 50, a common therapy for gastric and breast cancers, which indicates that expression and mutation status of this gene may be relevant to an informed treatment strategy for pancreatic cancer. This evidence concerns the gene PDE4DIP and pancreatic neoplasm.